Telisotuzumab-vedotin

Drug Profile

Telisotuzumab-vedotin

Alternative Names: ABBV-399; ABT 399

Latest Information Update: 08 Jul 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator AbbVie
  • Class Antineoplastics; Auristatins; Immunoconjugates; Immunotoxins; Monoclonal antibodies
  • Mechanism of Action Proto oncogene protein c met inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Solid tumours

Most Recent Events

  • 02 Jun 2017 Adverse events, efficacy data from a phase I trial in Solid tumours presented at the 53rd Annual Meeting of American Society of Clinical Oncology (ASCO-2017)
  • 07 Oct 2016 Adverse events, efficacy and pharmacokinetics data from a phase I trial in Solid tumours presented at the 41st European Society for Medical Oncology Congress (ESMO-2016)
  • 31 Mar 2016 Phase I development of ABBV 399 is ongoing in the US
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top